Literature DB >> 21484380

Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Lutz S Freudenberg1, Walter Jentzen, Alexander Stahl, Andreas Bockisch, Sandra J Rosenbaum-Krumme.   

Abstract

(124)I-PET/CT has a high clinical potential in patients with differentiated thyroid cancer (DTC). Two aspects deserve special mention: staging of recurrent or residual disease and pretherapy dosimetry. Used in combination (124)I-PET and CT allows foci of highly specific (124)I uptake to be localized with a low radiation dose, which is specifically important in pretherapy diagnostics. In addition in the combination of FDG-PET and CT non-iodine-avid lesions may be detected and may be discriminated from simultaneously occurring iodine-positive lesions. In clinical applications, the pretherapy (124)I-PET dosimetry may result in a significant alteration in the therapeutic procedure compared to standard therapy using fixed therapeutic activities. In this context, (124)I-PET dosimetry is a useful procedure especially in advanced DTC, and allows the administration of safer and more effective radioiodine activities as well as earlier multimodal interventions compared to standard empirical protocols. This review summarizes the clinical data on (124)I-PET/CT in patients with DTC, and addresses future prospects.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21484380     DOI： 10.1007/s00259-011-1773-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


  63 in total

1.  Thyroid cancer dosimetry using clearance fitting.

Authors:  E E Furhang; S M Larson; P Buranapong; J L Humm
Journal:  J Nucl Med       Date:  1999-01       Impact factor: 10.057

2.  Investigational study of iodine-124 with a positron camera.

Authors:  R M Lambrecht; N Woodhouse; R Phillips; D Wolczak; A Qureshi; E D Reyes; C Graser; S Al-Yanbawi; A Al-Rabiah; W Meyer
Journal:  Am J Physiol Imaging       Date:  1988

3.  [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2)].

Authors:  M Dietlein; J Dressler; J Farahati; F Grünwald; B Leisner; E Moser; C Reiners; H Schicha; O Schober
Journal:  Nuklearmedizin       Date:  2004-08       Impact factor: 1.379

4.  Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma.

Authors:  Seyfettin Ilgan; A Ozgur Karacalioglu; Yuksel Pabuscu; G Kaan Atac; Nuri Arslan; Emel Ozturk; Bengul Gunalp; M Ali Ozguven
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-05       Impact factor: 9.236

5.  Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer.

Authors:  H R Maxon; S R Thomas; V S Hertzberg; J G Kereiakes; I W Chen; M I Sperling; E L Saenger
Journal:  N Engl J Med       Date:  1983-10-20       Impact factor: 91.245

6.  Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer.

Authors:  L S Freudenberg; G Antoch; W Jentzen; R Pink; J Knust; R Görges; S P Müller; A Bockisch; J F Debatin; W Brandau
Journal:  Eur Radiol       Date:  2004-06-30       Impact factor: 5.315

7.  Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.

Authors:  L S Freudenberg; C Frömke; T Petrich; R J Marlowe; W W Koska; W Brandau; E G Eising; E J Knust; A Bockisch; W Jentzen
Journal:  Exp Clin Endocrinol Diabetes       Date:  2009-10-23       Impact factor: 2.949

8.  124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.

Authors:  L S Freudenberg; W Jentzen; R Görges; T Petrich; R J Marlowe; J Knust; A Bockisch
Journal:  Nuklearmedizin       Date:  2007       Impact factor: 1.379

9.  The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer.

Authors:  F Capoccetti; B Criscuoli; G Rossi; F Ferretti; C Manni; E Brianzoni
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-10       Impact factor: 2.346

10.  Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET.

Authors:  Lutz S Freudenberg; Walter Jentzen; Stefan P Müller; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-20       Impact factor: 10.057
View more
  20 in total

Review 1.  The role of nuclear medicine in differentiated thyroid cancer.

Authors:  Susanne Kohlfürst
Journal:  Wien Med Wochenschr       Date:  2012-07-20

2.  Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of patients with differentiated thyroid cancer.

Authors:  Laurent Dercle; Désirée Deandreis; Marie Terroir; Sophie Leboulleux; Jean Lumbroso; Martin Schlumberger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06       Impact factor: 9.236

Review 3.  The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview.

Authors:  Giorgio Treglia; Barbara Muoio; Luca Giovanella; Massimo Salvatori
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-02       Impact factor: 2.503

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

5.  Comparing pre-therapeutic 124I and 131I uptake tests with intra-therapeutic 131I uptake in benign thyroid disorders.

Authors:  Falk Gühne; Christian Kühnel; Martin Freesmeyer
Journal:  Endocrine       Date:  2017-03-07       Impact factor: 3.633

6.  (124)I-PET Assessment of Human Sodium Iodide Symporter Reporter Gene Activity for Highly Sensitive In Vivo Monitoring of Teratoma Formation in Mice.

Authors:  Sebastian Lehner; Cajetan Lang; Georgios Kaissis; Andrei Todica; Mathias Johannes Zacherl; Guido Boening; Christine Spitzweg; Nadja Herbach; Wolfgang-Michael Franz; Bernd Joachim Krause; Gustav Steinhoff; Peter Bartenstein; Marcus Hacker; Robert David
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

7.  Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT?

Authors:  I Binse; T D Poeppel; M Ruhlmann; B Gomez; L Umutlu; A Bockisch; S J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-19       Impact factor: 9.236

Review 8.  Prognostic and predictive value of nuclear imaging in endocrine oncology.

Authors:  Giorgio Treglia; Bernard Goichot; Luca Giovanella; Elif Hindié; Abhishek Jha; Karel Pacak; David Taïeb; Thomas Walter; Alessio Imperiale
Journal:  Endocrine       Date:  2019-11-16       Impact factor: 3.633

9.  ¹²⁴I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy ¹³¹I SPECT/CT.

Authors:  Cecile de Pont; Servais Halders; Jan Bucerius; Felix Mottaghy; Boudewijn Brans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-23       Impact factor: 9.236

10.  Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.

Authors:  Amir Sabet; Ina Binse; Hong Grafe; Samer Ezziddin; Rainer Görges; Thorsten D Poeppel; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-27       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.